LEP and ovarian carcinoma: Treatment with recombinant leptin was found to contribute to ovarian cancer cell migration, invasion, peritoneal metastasis and epithelial-mesenchymal transition (EMT), and the malignant phenotypes were caused by activation of the PI3K/Akt/mTOR signaling pathway [42].